Eli Lilly ( LLY -0.14%) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 ...

Eli Lilly’s strong position in GLP-1 drugs is overlooked by the market. Find out why LLY stock is a buy even as others pull ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...

Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded ...

In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...

Also Read: 99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly’s Detailed Phase 3 Data Shows ...

The Biden administration is proposing a major expansion of how Medicare and Medicaid cover the weight-loss drugs Wegovy and ...

Eli Lilly And Co (NYSE:LLY) shares are trading higher Tuesday after the Biden-Harris Administration proposed a new rule to ...

Should you forget Eli Lilly and buy this magnificent biotech instead? Let's find out. Image source: Getty Images. Viking's ...